AHL
HBIO icon

Abel Hall LLC’s Harvard Bioscience HBIO Stock Holding History

Abel Hall LLC’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,528
Closed -$16.9K – 883
2025
Q4 		$16.9K Sell
2,528
-693
-22% -$4.11K ﹤0.01% 704
2025
Q3 		$14.1K Sell
3,221
-512
-14% -$2.43K 0.01% 320
2025
Q2 		$16.6K Buy
+3,733
New +$15.6K 0.01% 272

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Abel Hall LLC's HBIO Position: Q1 2026 in Review

Abel Hall LLC sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 2,528 shares — an estimated $16.9K sold.

Abel Hall LLC first reported a position in HBIO in Q2 2025 and held it in 3 quarters. The position peaked at $16.9K in Q4 2025. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Abel Hall LLC reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Abel Hall LLC sold 2,528 Harvard Bioscience shares in Q1 2026, an estimated $16.9K.
  • Abel Hall LLC first reported a position in Harvard Bioscience in Q2 2025 and held it in 3 quarters.
  • Abel Hall LLC's Harvard Bioscience position peaked at $16.9K in Q4 2025.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.